nucleosome diagnostics

VolitionRx Prices $2.3M Registered Direct Offering

Proceeds from the offering will be used for research and continued product development, clinical studies, and product commercialization.

The firm hopes to include its lung cancer assay in Taiwan's national cancer screening program while developing sepsis and ovarian cancer assays.

The Nevada-based epigenetics firm will receive half the money through an unsecured loan and half through the sale of restricted common stock.

DXOCRO will conduct large-scale clinical utility studies of Volition's Nu.Q NETs and Nu.Q Cancer tests at multiple sites in the US.

The non-dilutive funding will go toward an early-access program for Volition's Nu.Q nucleosome quantification technology in the US, EU, and UK.

Jan 12, 2021

Jan 5, 2021

May 21, 2020

May 20, 2020

Dec 5, 2019

Aug 8, 2018

Mar 9, 2018

Aug 23, 2017